Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Recommendation of “Buy” by Analysts
Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Get Free Report) has been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the […]
More Stories
Two Sigma Investments LP Raises Holdings in Nextdoor Holdings, Inc. (NYSE:KIND)
Two Sigma Investments LP increased its position in Nextdoor Holdings, Inc. (NYSE:KIND – Free Report) by 88.7% during the fourth...
Two Sigma Investments LP Cuts Stake in Chemed Co. (NYSE:CHE)
Two Sigma Investments LP decreased its holdings in Chemed Co. (NYSE:CHE – Free Report) by 38.0% in the fourth quarter,...
Two Sigma Advisers LP Decreases Stock Position in Old Second Bancorp, Inc. (NASDAQ:OSBC)
Two Sigma Advisers LP reduced its position in Old Second Bancorp, Inc. (NASDAQ:OSBC – Free Report) by 14.9% in the...
Two Sigma Advisers LP Lowers Stock Holdings in Open Lending Co. (NASDAQ:LPRO)
Two Sigma Advisers LP reduced its position in Open Lending Co. (NASDAQ:LPRO – Free Report) by 21.0% in the 4th...
Two Sigma Investments LP Reduces Holdings in Sensata Technologies Holding plc (NYSE:ST)
Two Sigma Investments LP decreased its holdings in Sensata Technologies Holding plc (NYSE:ST – Free Report) by 2.8% during the...
Two Sigma Advisers LP Sells 198,600 Shares of Erasca, Inc. (NASDAQ:ERAS)
Two Sigma Advisers LP reduced its position in shares of Erasca, Inc. (NASDAQ:ERAS – Free Report) by 25.0% during the...